A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

• Paliperidone Palmitate 3-Month Formulation (PP3M) (Drug), also known as Trevicta: No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.

Primary outcomes

• Participant's Experience with PP3M Treatment [1 day]: Participant's experience with paliperidone palmitate 3-month formulation (PP3M) treatment will be evaluated qualitatively through an online questionnaire. Each questionnaire will include a total of approximately 30 to 35 multiple choice questions related to following categories: Impact on relationship/ interaction between medical team and carer/ patient, Involvement in treatment decision, Reasons for PP3M, Impact of treatment on patient, Impact of treatment on carer and General experience with PP3M.

Secondary outcomes

• Responses to the Questionnaires [1 day]: The response to the questionnaires of the corresponding physician, and the corresponding nurse and carer where applicable, for each participant will be collected for the following categories: Impact on relationship/ interaction between medical team and carer/ patient, Involvement in treatment decision, Reasons for PP3M, Impact of treatment on patient, Impact of treatment on carer and General experience with PP3M.
• Clinical Global Impression-Severity (CGI-S) Score [1 day]: The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. The CGI-S permits a global evaluation of the participant's condition at a given time.
• Positive and Negative Syndrome Scale (PANSS) - Lack of Judgement and Insight's Score (G12 Item) [1 day]: The PANSS is a validated scale specific for the measurement of the symptoms of schizophrenia. The neuropsychiatric symptoms of schizophrenia are assessed across 3 subscales comprising a total of 30 items; the positive \[P\] and negative \[N\] subscales each includes 7 items, while the general psychopathology \[G\] subscale includes 16 items. Lack of judgment and insight's score is 12th item of the general psychopathology subscale (G12 item) of PANSS with score ranges from 1 to 7. Higher scores indicate worsening.
• European Quality of Life (EuroQol) 5-Dimension 5-Level (EQ 5D-5L) Questionnaire General Health Status Score [1 day]: EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The responses to the 5 dimensions are used to compute a single utility score ranging from zero (worst health state) to 1 (better health state) representing the general health status of the individual.

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Have a diagnosis of schizophrenia (according to International Classification of Diseases \[ICD\]-10)
* Be currently receiving PP3M and have previously received 4 to 6 injections of PP3M
* Have the required language skills to participate in the online questionnaire, in the opinion of the physician
* Be able and willing to provide their informed consent for study participation

Exclusion Criteria:

* Has received involuntary treatment with PP3M
* Was switched to PP3M treatment within a clinical trial

• Janssen-Cilag International NV Clinical Trial, Study director, Janssen-Cilag International NV